An analysis of cancer patients who were infected with the coronavirus and treated at Memorial Sloan Kettering Cancer Center in New York City suggests certain risk factors may predict more severe COVID-19.

by Anna Azvolinsky

Following the approval of the first immunotherapy for breast cancer by the U.S. Food and Drug Administration in March 2019, experts at the San Antonio Breast Cancer Symposium discussed avenues for further development.

by Marci A. Landsmann

Patients with advanced cancer often go to rehabilitation facilities after a hospital stay in hopes of gaining the strength for further treatment, but the majority do not go on to receive additional cancer therapy, a study reports.

by Ashley P. Taylor

Immune checkpoint inhibitors can be effective treatments for elderly people with some types of advanced cancer, but more information is needed on their risks and benefits in this group.

by Emma Yasinski

Drug developers behind currently approved checkpoint inhibitors discuss the pros and cons of competition in the field.

by Kate Yandell

Some researchers believe that immunotherapy occasionally causes cancer to grow faster, a phenomenon dubbed hyper-progression.

by Kate Yandell

Medical oncologist Leisha A. Emens discusses the significance of the first U.S. Food and Drug Administration approval of an immunotherapy treatment for breast cancer.

by Anna Azvolinsky

Through the Angiosarcoma Project, researchers are partnering with patients to learn about a rare cancer.

by Ashley P. Taylor

A trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non-small cell lung cancer treatment.

by Brad Jones

At the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors' molecular characteristics, not to their tissues of origin.

by Kate Yandell